ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2020

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.

Lotte Westerink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.